Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.

Keywords

Carboplatin, Medicine, Toxicity, Chemotherapy, Cisplatin

References

• M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.Cora N. Sternberg, Alan Yagoda, Howard I. Scher — 1988
• Nephrotoxicity of cis‐platinum (II) dichlorodiammineJames J. Stark, Stephen B. Howell — 1978
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.C. Logothetis, F. H. Dexeus, Laura Finn — 1990
• Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).M. van Glabbeke, J. Renard, Herbert M. Pinedo — 1988
• The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.Edmund A. Gehan — 1961
• Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder.Nils Raabe, Sophie D. Fosså, Gunnar Parö — 1989
• Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer.R.T.D. Oliver, HH Kwok, W J Highman — 1986
• Carboplatin for advanced bladder cancer.Eugenio Marcuello, Miguel Izquierdo, J. R. Germa — 1990
• A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.Brian L. Hillcoat, Derek Raghavan, JP Matthews — 1989
• Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract.Janardan D. Khandekar, Paul Elson, W D DeWys — 1985
• Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial.M. Troner, Robert Birch, G Omura — 1987
• The role of cisplatin-based chemotherapy in advanced urothelial tract cancer.A Yagoda — 1989
• Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP).Creaven Pj, Stefan Madajewicz, Lakshmi Pendyala — 1983
• Hypersensitivity reactions to CHIP.C. J. Rodenburg, J. van Ulsen, C. Seynaeve — 1990
• Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder.G. Stoter, T. A. W. Splinter, J. Anthony Child — 1987
• A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladderJ. Barnes, A. Calvert, L. Freedman — 1987

Cited by

• Use of calcium channel blockers and breast carcinoma risk in postmenopausal womenAnnette L. Fitzpatrick, Janet R. Daling, Curt D. Furberg — 1997
• Emerging Drug Treatments for Solid TumoursJan H.M. Schellens, Linda Pronk, Jaap Verweij — 2012
• A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.Joaquim Bellmunt, Ronald de Wit, Joan Albanell — 2001
• The status of platinum anticancer drugs in the clinic and in clinical trials.Nial Wheate, Shonagh Walker, Gemma E. Craig — 2010
• A systematic overview of chemotherapy effects in urothelial bladder cancer.Sten Nilsson, Peter Ragnhammar, Peter Nygren — 2001
• Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.Maria De Santis, Joaquim Bellmunt, Graham M. Mead — 2009
• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.Maria De Santis, Joaquim Bellmunt, Graham M. Mead — 2012
• The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsTimothy C. Johnstone, Kogularamanan Suntharalingam, Stephen J. Lippard — 2016
• Hypersensitivity reactions to cisplatin and carboplatin--a report on six cases.Mark Saunders, Christopher P. Denton, Mary O’Brien — 1992
• Hypoxia-targeted drug deliveryAmit Sharma, Jonathan F. Arambula, Seyoung Koo — 2019
• Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.Maria Koufopoulou, Paulo Miranda, Paulina Kaźmierska — 2020
• Metallo-Drugs in Cancer Therapy: Past, Present and FutureRoxana Liana Lucaciu, Adriana Corina Hangan, Bogdan Sevastre — 2022
• Nanostructured mesoporous silica carriers for platinum-based conjugates with anti-inflammatory agents.Ivana Predarska, Goran N. Kaluđerović, Evamarie Hey‐Hawkins — 2024

Related papers

• Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapyGerrit Los, Els M.E. Verdegaal, P.H.A. Mutsaers — 2004
• In vitro cytotoxicity of cisplatin combined with carboplatin on osteosarcoma cell line OS-732Fan Shunwu — 2004
• Inhibitory Effect of Metal Complexes Cisplatin and Carboplatin of Cervical Cancer CellsXiaojing Nie, Huiru Cao, Wumidan Abudureheman — 2023
• THE COMPARISION OF STUDY BETWEEN CISPLATIN AND CARBOPLATIN IN CHEMOTHERAPY OF CERVICAL CANCERMin Hu — 2006
• Thermochemotherapy with cisplatin or carboplatin in the BT4 rat glioma in vitro and in vivo.Baard‐Christian Schem, Olav Mella, Olav Dahl — 1992
• Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonadsCaroline M Allen, Federica Lopes, Rod T. Mitchell — 2020
• Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assayJames Fanning, W Biddle, Martin H. Goldrosen — 1990
• New Cisplatin Analogues in DevelopmentRaymond B. Weiss, Michaele C. Christian — 1993